THE RELATION OF BREAST CANCER TISSUE AND ITS CLINICOPATHOLOGIC FACTORS WITH EXPRESSION OF BCL-2 PROTEIN
Keywords:
Breast cancer, Bcl-2, immunohistochemical methodAbstract
In women worldwide the most common malignant neoplasm is breast cancer, with a lifetime risk of 1 out of every 8 women. The association between Bcl-2 and breast cancer development and progression is still unclear, but a relationship between unfavorable clinical outcome and Bcl-2 overexpression is to be expected. The aim of this study is the detection of Bcl-2 in breast cancer tissues, utilizing the immunohistochemical methods and its association with various clinicopathologic parameters as age, family history, grade and stage.
References
Kari H. and Charlotta G. (2002) Morphological types of breast cancer in family members and multiple primary tumours; is morphology genetically determined?. Breast Cancer Research, Vol 4, No 4, pp. 1-6.
Rosai J. (2004) Rosai and Ackerman’s Surgical Pathology. Vol. 2, 9th ed. Edinburgh: Mosby, pp. 1794-1812.
Gonzalez-Campora et al (2000) Apoptosis in breast carcinoma. Pathol. Res. Pract, Vol 196, pp. 167-174.
Dowsett et al (1999) Clinical studies of apoptosis and proliferation in breast cancer. Endocrine-Related Cancer, Vol 6, pp. 25-28.
Williams M.M., and Cook R.S. (2015) Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?.Oncotarget, Vol 6, No 6, pp. 3519.
Zhou et al (2017) Curcumin reduces mitomycin C resistance in breast cancer stem cells by regulating Bcl-2 family-mediated apoptosis. Cancer Cell International, Vol 17, No 1, pp. 1-13.
Tanaka et al (2000) Expression of surviving and its relationship to loss of apoptosis in breast carcinomas. Clinical Cancer Research, Vol 6, No 1, pp. 127-134.
Tao et al (2015) Breast cancer: epidemiology and etiology. Cell biochemistry and biophysics, Vol 72, No2, pp. 333-338.
Ohmura et al (2000) Telomerase activity and Bcl-2 expression in non-small cell lung cancer. Clinical Cancer Research, Vol 6, No 8, pp. 2980-2987.
Zhang et al (2005) Correlation of mammographical imaging signs with expression of Bcl-2 and Bax proteins in breast cancer. Journal of Cancer Molecules, Vol 1, No 2, pp. 99-102.
Merino et al (2016) Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. Oncogene, Vol 35, No 15, pp. 1877-1887.
Honma et al (2015) Differences in clinical importance of Bcl-2 in breast cancer according to hormone recepters status or adjuvent endocrine therapy. BMC Cancer, Vol 15, No 1, pp. 698.
Seong et al (2015) Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2- negative breast cancer. Breast Cancer Research and Treatment, Vol 150, No 1, pp. 141-148.
(14) Bhatavdekar et al (2000) Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: A multivariate analysis. Annals of Surgical Oncology, Vol 7, No 4, pp.305-311.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
